A World Changing Friendship

Map pinpoints are not exact. They are a representation of the number of clinical trials in each state.

The Vera Bradley Foundation for Breast Cancer started with friendship. Mary Sloan, a longtime friend of Vera Bradley co-founders Barbara Bradley Baekgaard and Patricia Miller, joined them as one of company’s first sales representatives when the company was founded in 1987. As good friends do, these women eagerly looked forward to all that the future held for their tight-knit circle. Sadly, in the early 1990’s, Mary’s life was cut short by breast cancer.

Mary Sloan

Having lost Mary – a college roommate, a cherished friend, an amazing mother, and a treasured co-worker – Barb and Pat were moved to action and the Vera Bradley Foundation for Breast Cancer was born. The Foundation has grown to become a globally recognized not-for-profit organization funding some of the most gifted and accomplished breast cancer researchers in the world. With its roots firmly planted in friendship, Mary Sloan’s life continues to impact women around the globe.

As clinical trials originating in the labs of the Vera Bradley Foundation Center for Breast Cancer Research spread hope across the country, so does the Foundation’s reach and impact. In fact, because of one special friendship, the Vera Bradley Foundation for Breast Cancer currently receives donations from all 50 states, the District of Columbia, Puerto Rico, and 15 other countries around the world!

Through campaigns, Foundation hosted events, partner events, and online initiatives, we continue to raise funds for breast cancer research. Connected by a passion to find a cure, the global impact of the research and the number of friends lending support grows by the day.

Clinical Trials

BRE12-158
Genomically Driven Therapy after Preoperative Chemotherapy in Triple Negative Breast Cancer

BRE18-334
PERSEVERE, Phase II Triple Negative Breast Cancer precision therapy trial

IUSCC-0684 
A Phase I Study of ASTX727 plus Talazoparib in Patients with TNBC or Hormone Resistant Metastatic BC 

J13104
Phase II Study of Partial Breast Irradiation and Sequential vs. Concurrent Chemotherapy (PBI 3.0)

EAZ171
Docetaxel or Paclitaxel and risk of peripheral neuropathy in African American women

---